Timo Heidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timo Heidt has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Christoph Bode
Department of Cardiology and Angiology I, University Heart Center Freiburg – Bad Krozingen, Medical Faculty, University of Freiburg, Freiburg, Germany
8 shared publicationsConstantin von Zur Mühlen
Department of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany
7 shared publications- Constantin von Zur Mühlen
Department of Cardiology and Angiology, Faculty of Medicine, Medical Centre-University of Freiburg, University Heart Centre Freiburg-Bad Krozingen, Freiburg, Germany.
7 shared publications Ingo Hilgendorf
Department of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany
6 shared publications- Dennis Wolf
Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Germany (C.A.E., T.-S.D., U.Z., C.v.z.M., D. Wolf, D. Westermann)
5 shared publications - Michael Bock
Division of Medical Physics, Department of Diagnostic and Interventional Radiology Medical Center – University of Freiburg, Faculty of Medicine – University of Freiburg Freiburg Germany
5 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 April 2025
- Published by Springer Nature in Nature Cell Biology
- Vol. 27 (4) , 591-604
Modulation of bone marrow haematopoietic stem cell activity as a therapeutic strategy after myocardial infarction: a preclinical study
Myocardial infarction (MI) is a major global health concern. Although myeloid cells are crucial for tissue repair in emergency haematopoiesis after MI, excessive myelopoiesis can exacerbate scarring and impair cardiac function. Bone marrow (BM) haematopoietic stem cells (HSCs) have the unique capability to replenish the haematopoietic system, but their role in emergency haematopoiesis after MI has not yet been established. Here we collected human sternal BM samples from over 150 cardiac surgery patients, selecting 49 with preserved cardiac function. We show that MI causes detrimental transcriptional and functional changes in human BM HSCs. Lineage tracing experiments suggest that HSCs are contributors of pro-inflammatory myeloid cells infiltrating cardiac tissue after MI. Therapeutically, enforcing HSC quiescence with the vitamin A metabolite 4-oxo-retinoic acid dampens inflammatory myelopoiesis, thereby modulating tissue remodelling and preserving long-term cardiac function after MI.
- 2 April 2025
- Published by Springer Nature in Nature Cell Biology
- Vol. 27 (4) , 591-604
Top Cited PapersOpen AccessModulation of bone marrow haematopoietic stem cell activity as a therapeutic strategy after myocardial infarction: a preclinical study
Myocardial infarction (MI) is a major global health concern. Although myeloid cells are crucial for tissue repair in emergency haematopoiesis after MI, excessive myelopoiesis can exacerbate scarring and impair cardiac function. Bone marrow (BM) haematopoietic stem cells (HSCs) have the unique capability to replenish the haematopoietic system, but their role in emergency haematopoiesis after MI has not yet been established. Here we collected human sternal BM samples from over 150 cardiac surgery patients, selecting 49 with preserved cardiac function. We show that MI causes detrimental transcriptional and functional changes in human BM HSCs. Lineage tracing experiments suggest that HSCs are contributors of pro-inflammatory myeloid cells infiltrating cardiac tissue after MI. Therapeutically, enforcing HSC quiescence with the vitamin A metabolite 4-oxo-retinoic acid dampens inflammatory myelopoiesis, thereby modulating tissue remodelling and preserving long-term cardiac function after MI.
- Open Access
- 15 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (45) , e2407704
Thermally Drawn Polymeric Catheters for MR‐Guided Cardiovascular Intervention
Cardiovascular diseases (CVDs), including congenital heart diseases (CHD), present significant global health challenges, emphasizing the need for safe and effective treatment modalities. Fluoroscopy‐guided endovascular interventions are widely utilized but raise concerns about ionizing radiation, especially in pediatric cases. Magnetic resonance imaging (MRI) offers a radiation‐free alternative with superior soft tissue visualization and functional insights. However, the lack of compatible instruments remains a major obstacle. An adapted thermal drawing platform that enables low‐cost and rapid prototyping of instruments for MR‐guided endovascular interventions is introduced. This platform is demonstrated through the development of two exemplary catheter systems: a tendon‐driven steerable catheter with helical lumina and an active tracking Tiger‐shaped catheter with an embedded coaxial wire. These catheters exhibit mechanical properties comparable to commercial counterparts and show promising outcomes in both in vitro and in vivo feasibility testing. This scalable thermal drawing platform addresses the limitations of existing manufacturing approaches and facilitates the exploration of diverse designs, potentially accelerating advancements in catheter technologies for MR‐guided cardiovascular interventions.
- 15 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (45) , e2407704
Open AccessThermally Drawn Polymeric Catheters for MR‐Guided Cardiovascular Intervention
Cardiovascular diseases (CVDs), including congenital heart diseases (CHD), present significant global health challenges, emphasizing the need for safe and effective treatment modalities. Fluoroscopy‐guided endovascular interventions are widely utilized but raise concerns about ionizing radiation, especially in pediatric cases. Magnetic resonance imaging (MRI) offers a radiation‐free alternative with superior soft tissue visualization and functional insights. However, the lack of compatible instruments remains a major obstacle. An adapted thermal drawing platform that enables low‐cost and rapid prototyping of instruments for MR‐guided endovascular interventions is introduced. This platform is demonstrated through the development of two exemplary catheter systems: a tendon‐driven steerable catheter with helical lumina and an active tracking Tiger‐shaped catheter with an embedded coaxial wire. These catheters exhibit mechanical properties comparable to commercial counterparts and show promising outcomes in both in vitro and in vivo feasibility testing. This scalable thermal drawing platform addresses the limitations of existing manufacturing approaches and facilitates the exploration of diverse designs, potentially accelerating advancements in catheter technologies for MR‐guided cardiovascular interventions.
- Open Access
- 16 September 2024
- Published by Springer Nature in Clinical Research in Cardiology
Development of a patient-centered app in Germany as a special health and organizational support by surveying patients with cardiovascular diseases
Background: A variety of health-related mobile applications (apps) and wearables often encompass a narrow application area. Our study therefore aims to provide the basis for the development of an app that comprehensively assists patients to deal with their disease in the best possible way and that improves the course of the disease in the long term. Methods: We conducted a multicenter analysis of patients using a questionnaire study at two German clinics and surveyed 100 patients with cardiovascular disease. For the analysis of the interviews, particularly Likert scales were used. Results: 24.0% were female, median age was 62.5 years. Leading causes for hospitalization were coronary artery disease (40.0%) and heart failure (22.0%). The most frequent pre-existing conditions were arterial hypertension (55.0%), atrial fibrillation or atrial flutter (31.0%), and again coronary artery disease (31.0%). Typical disease associated feelings were fear for life (43.0%) and uncertainty (43.0%). When considering future management of the disease, 75.0% felt motivated, 70.0% felt confident, and 68.0% felt hopeful. Of the patients surveyed, 60.0% indicated a willingness to use the app and another 24.0% were potentially willing to do so. Furthermore, significantly more patients < 63 years stated a willingness or potential willingness to use the app (p = 0.029). For those considering an app usage in general, the most favoured features were a document management (81.8%) and a medication management (65.9%). While only 36.4% indicated that the app could at least partially alleviate their worries, 94.3% expected a reduction in organizational effort. With respect to age groups, there was no significant difference (organizational effort: p = 0.239; worries: p = 0.275). Conclusions: Particularly younger patients < 63 years with cardiovascular disease show a substantial willingness to use an app as a special health support, particularly in terms of document and medication management. They especially hope for a reduction in organizational effort. Graphical
- 16 September 2024
- Published by Springer Nature in Clinical Research in Cardiology
Open AccessDevelopment of a patient-centered app in Germany as a special health and organizational support by surveying patients with cardiovascular diseases
Background: A variety of health-related mobile applications (apps) and wearables often encompass a narrow application area. Our study therefore aims to provide the basis for the development of an app that comprehensively assists patients to deal with their disease in the best possible way and that improves the course of the disease in the long term. Methods: We conducted a multicenter analysis of patients using a questionnaire study at two German clinics and surveyed 100 patients with cardiovascular disease. For the analysis of the interviews, particularly Likert scales were used. Results: 24.0% were female, median age was 62.5 years. Leading causes for hospitalization were coronary artery disease (40.0%) and heart failure (22.0%). The most frequent pre-existing conditions were arterial hypertension (55.0%), atrial fibrillation or atrial flutter (31.0%), and again coronary artery disease (31.0%). Typical disease associated feelings were fear for life (43.0%) and uncertainty (43.0%). When considering future management of the disease, 75.0% felt motivated, 70.0% felt confident, and 68.0% felt hopeful. Of the patients surveyed, 60.0% indicated a willingness to use the app and another 24.0% were potentially willing to do so. Furthermore, significantly more patients < 63 years stated a willingness or potential willingness to use the app (p = 0.029). For those considering an app usage in general, the most favoured features were a document management (81.8%) and a medication management (65.9%). While only 36.4% indicated that the app could at least partially alleviate their worries, 94.3% expected a reduction in organizational effort. With respect to age groups, there was no significant difference (organizational effort: p = 0.239; worries: p = 0.275). Conclusions: Particularly younger patients < 63 years with cardiovascular disease show a substantial willingness to use an app as a special health support, particularly in terms of document and medication management. They especially hope for a reduction in organizational effort. Graphical
- Open Access
Non-preferential, but detrimental accumulation of macrophages with clonal hematopoiesis-driver mutations in cardiovascular tissues
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is an acquired genetic risk factor for cardiovascular (CV) disease, supposedly mediated by pro-inflammatory recruited monocytes 1–15 . However, how these cells and their progeny behave in the CV tissue remains unclear. Here, we studied human carotid artery plaque and heart tissue samples from DNMT3A or TET2 mutation carriers to quantify the relative accumulation of mutated macrophages and to characterize tissue macrophages from carriers compared to non-carriers. Using droplet digital polymerase chain reaction (ddPCR), we detected similar sizes of CHIP clones in circulating monocytes and macrophages from atheromas and heart tissues, even among CCR2+ (infiltrative), and CCR2– (resident) cardiac macrophages. Using bulk RNA-sequencing (RNA-seq), we revealed a pro-inflammatory gene profile of myeloid cells from CHIP carriers compared to non-carriers. In summary, quantitatively, CHIP mutated myeloid cells did not preferentially accumulate in CV tissues, but qualitatively, they expressed a more disease-prone phenotype.
Open AccessNon-preferential, but detrimental accumulation of macrophages with clonal hematopoiesis-driver mutations in cardiovascular tissues
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is an acquired genetic risk factor for cardiovascular (CV) disease, supposedly mediated by pro-inflammatory recruited monocytes 1–15 . However, how these cells and their progeny behave in the CV tissue remains unclear. Here, we studied human carotid artery plaque and heart tissue samples from DNMT3A or TET2 mutation carriers to quantify the relative accumulation of mutated macrophages and to characterize tissue macrophages from carriers compared to non-carriers. Using droplet digital polymerase chain reaction (ddPCR), we detected similar sizes of CHIP clones in circulating monocytes and macrophages from atheromas and heart tissues, even among CCR2+ (infiltrative), and CCR2– (resident) cardiac macrophages. Using bulk RNA-sequencing (RNA-seq), we revealed a pro-inflammatory gene profile of myeloid cells from CHIP carriers compared to non-carriers. In summary, quantitatively, CHIP mutated myeloid cells did not preferentially accumulate in CV tissues, but qualitatively, they expressed a more disease-prone phenotype.
- Open Access
An Activation-Specific Anti-Mac-1 Designed-Ankyrin-Repeat-Protein Attenuates Colitis in Mice
(1) Background: Inflammatory bowel diseases are complex and multifactorial disorders of unknown etiology. The extravasation of activated leukocytes is a critical step in the pathogenesis of these diseases. Leukocyte integrin Mac-1 (αMβ2; CD11b/CD18) is crucial for the extravasation of myeloid cells, and a novel activation-specific anti-Mac-1 Designed Ankyrin Repeat protein (DARPin F7) is a promising therapeutic agent for inflammatory diseases. In its activated conformation, Mac-1 expresses the high-affinity binding site I-domain, which the DARPin F7 selectively targets. In our study, we aimed to explore the therapeutic potential of anti-Mac-1 DARPin F7 in murine dextrane sodium sulfate (DSS)-induced colitis. (2) Methods: C57BL/6J mice received 3% DSS drinking water for five days, followed by normal drinking water for one week. The mice were treated with DARPin F7 or a control substance daily via intraperitoneal injections. Disease activity index (DAI), colon length, myeloperoxidase (MPO) activity measurements, H&E staining, and qRT-PCR were conducted after euthanizing the mice on day 12. (3) Results: Treatment with DARPin F7 resulted in less pronounced colon shortening and significantly lower histological scores. The DARPin F7-treated animals experienced substantially less disease and myeloperoxidase (MPO) activity. Animals that received DARPin F7 treatment suffered less weight loss and recovered from the weight loss more efficiently. Treatment with DARPin F7 also led to significantly reduced mRNA expression of inflammatory cytokines. (4) Conclusion: Anti-Mac-1 treatment markedly reduced disease activity and inflammatory reaction accompanying DSS-induced colitis in mice.
Open AccessAn Activation-Specific Anti-Mac-1 Designed-Ankyrin-Repeat-Protein Attenuates Colitis in Mice
(1) Background: Inflammatory bowel diseases are complex and multifactorial disorders of unknown etiology. The extravasation of activated leukocytes is a critical step in the pathogenesis of these diseases. Leukocyte integrin Mac-1 (αMβ2; CD11b/CD18) is crucial for the extravasation of myeloid cells, and a novel activation-specific anti-Mac-1 Designed Ankyrin Repeat protein (DARPin F7) is a promising therapeutic agent for inflammatory diseases. In its activated conformation, Mac-1 expresses the high-affinity binding site I-domain, which the DARPin F7 selectively targets. In our study, we aimed to explore the therapeutic potential of anti-Mac-1 DARPin F7 in murine dextrane sodium sulfate (DSS)-induced colitis. (2) Methods: C57BL/6J mice received 3% DSS drinking water for five days, followed by normal drinking water for one week. The mice were treated with DARPin F7 or a control substance daily via intraperitoneal injections. Disease activity index (DAI), colon length, myeloperoxidase (MPO) activity measurements, H&E staining, and qRT-PCR were conducted after euthanizing the mice on day 12. (3) Results: Treatment with DARPin F7 resulted in less pronounced colon shortening and significantly lower histological scores. The DARPin F7-treated animals experienced substantially less disease and myeloperoxidase (MPO) activity. Animals that received DARPin F7 treatment suffered less weight loss and recovered from the weight loss more efficiently. Treatment with DARPin F7 also led to significantly reduced mRNA expression of inflammatory cytokines. (4) Conclusion: Anti-Mac-1 treatment markedly reduced disease activity and inflammatory reaction accompanying DSS-induced colitis in mice.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Robotic-assisted PCI – insights from a monocenter registry
Robotics in interventional cardiology is a rapidly evolving technique, which is still in an early phase of development and clinical application. Beside the pivotal studies, there is limited real world data on success rates and safety of this new technology. To investigate the success rate as well as the safety profile of robotic-assisted percutaneous coronary intervention (R-PCI) and compare it with manual PCI (M-PCI). We report preliminary data of our ongoing, prospective FRiK registry, started in mid 2021. This registry focuses on success rates and safety, radiation dose of patients and personnel, long-term outcome (after 6, 12 and 24 months), as well as on economic aspects and the learning curve of the interventionalists. Moreover, the R-PCI is compared with the M-PCI in these categories. So far, 51 patients (age 69 (62–80) years, BMI 28.4 (25.2–32) kg/m2, 74.5% male), received R-PCI. PCI success rate was 100%, with 15% requiring manual assistance (Figure 1). Rate of complications (myocardial infarction after PCI, dissection, stent thrombosis, pericardial effusion, target lesion revascularization and MACE (major adverse cardiovascular events) was 0%. Compared with 41 M-PCI patients (Table 1), treated by the same interventionalists, there was a higher median procedural time (diagnostic and intervention) 106 (82–127) min vs. 71 (54–93) min (p2 vs. 4193.9 (2759.9–6254.3) cGy cm2 (p=0.487) and contrast volume use 200 (150–280) ml vs. 180 (145–255) ml (p=0.587). Preliminary results of R-PCI showed a high success rate, low rates for need of manual assistance, and a very high safety profile without any complications. The dose-area product and contrast volume use were comparable between R-PCI and M-PCI, whereas R-PCI showed a longer procedural and fluoroscopy time. Future steps will include a larger number of cases and definitions of patient cases with optimal eligibility for R-PCI. Type of funding sources: None. Figure 1. Efficacy and safety of R-PCI
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessRobotic-assisted PCI – insights from a monocenter registry
Robotics in interventional cardiology is a rapidly evolving technique, which is still in an early phase of development and clinical application. Beside the pivotal studies, there is limited real world data on success rates and safety of this new technology. To investigate the success rate as well as the safety profile of robotic-assisted percutaneous coronary intervention (R-PCI) and compare it with manual PCI (M-PCI). We report preliminary data of our ongoing, prospective FRiK registry, started in mid 2021. This registry focuses on success rates and safety, radiation dose of patients and personnel, long-term outcome (after 6, 12 and 24 months), as well as on economic aspects and the learning curve of the interventionalists. Moreover, the R-PCI is compared with the M-PCI in these categories. So far, 51 patients (age 69 (62–80) years, BMI 28.4 (25.2–32) kg/m2, 74.5% male), received R-PCI. PCI success rate was 100%, with 15% requiring manual assistance (Figure 1). Rate of complications (myocardial infarction after PCI, dissection, stent thrombosis, pericardial effusion, target lesion revascularization and MACE (major adverse cardiovascular events) was 0%. Compared with 41 M-PCI patients (Table 1), treated by the same interventionalists, there was a higher median procedural time (diagnostic and intervention) 106 (82–127) min vs. 71 (54–93) min (p2 vs. 4193.9 (2759.9–6254.3) cGy cm2 (p=0.487) and contrast volume use 200 (150–280) ml vs. 180 (145–255) ml (p=0.587). Preliminary results of R-PCI showed a high success rate, low rates for need of manual assistance, and a very high safety profile without any complications. The dose-area product and contrast volume use were comparable between R-PCI and M-PCI, whereas R-PCI showed a longer procedural and fluoroscopy time. Future steps will include a larger number of cases and definitions of patient cases with optimal eligibility for R-PCI. Type of funding sources: None. Figure 1. Efficacy and safety of R-PCI
- Open Access
- 30 March 2022
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 117 (1) , 1-17
P2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction
Emergency hematopoiesis is the driving force of the inflammatory response to myocardial infarction (MI). Increased proliferation of hematopoietic stem and progenitor cells (LSK) after MI enhances cell production in the bone marrow (BM) and replenishes leukocyte supply for local cell recruitment to the infarct. Decoding the regulation of the inflammatory cascade after MI may provide new avenues to improve post-MI remodeling. In this study, we describe the influence of adenosine diphosphate (ADP)-dependent P2Y12-mediated signaling on emergency hematopoiesis and cardiac remodeling after MI. Permanent coronary ligation was performed to induce MI in a murine model. BM activation, inflammatory cell composition and cardiac function were assessed using global and platelet-specific gene knockout and pharmacological inhibition models for P2Y12. Complementary in vitro studies allowed for investigation of ADP-dependent effects on LSK cells. We found that ADP acts as a danger signal for the hematopoietic BM and fosters emergency hematopoiesis by promoting Akt phosphorylation and cell cycle progression. We were able to detect P2Y12 in LSK, implicating a direct effect of ADP on LSK via P2Y12 signaling. P2Y12 knockout and P2Y12 inhibitor treatment with prasugrel reduced emergency hematopoiesis and the excessive inflammatory response to MI, translating to lower numbers of downstream progeny and inflammatory cells in the blood and infarct. Ultimately, P2Y12 inhibition preserved cardiac function and reduced chronic adverse cardiac remodeling after MI. P2Y12-dependent signaling is involved in emergency hematopoiesis after MI and fuels post-ischemic inflammation, proposing a novel, non-canonical value for P2Y12 antagonists beyond inhibition of platelet-mediated atherothrombosis.
- 30 March 2022
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 117 (1) , 1-17
Open AccessP2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction
Emergency hematopoiesis is the driving force of the inflammatory response to myocardial infarction (MI). Increased proliferation of hematopoietic stem and progenitor cells (LSK) after MI enhances cell production in the bone marrow (BM) and replenishes leukocyte supply for local cell recruitment to the infarct. Decoding the regulation of the inflammatory cascade after MI may provide new avenues to improve post-MI remodeling. In this study, we describe the influence of adenosine diphosphate (ADP)-dependent P2Y12-mediated signaling on emergency hematopoiesis and cardiac remodeling after MI. Permanent coronary ligation was performed to induce MI in a murine model. BM activation, inflammatory cell composition and cardiac function were assessed using global and platelet-specific gene knockout and pharmacological inhibition models for P2Y12. Complementary in vitro studies allowed for investigation of ADP-dependent effects on LSK cells. We found that ADP acts as a danger signal for the hematopoietic BM and fosters emergency hematopoiesis by promoting Akt phosphorylation and cell cycle progression. We were able to detect P2Y12 in LSK, implicating a direct effect of ADP on LSK via P2Y12 signaling. P2Y12 knockout and P2Y12 inhibitor treatment with prasugrel reduced emergency hematopoiesis and the excessive inflammatory response to MI, translating to lower numbers of downstream progeny and inflammatory cells in the blood and infarct. Ultimately, P2Y12 inhibition preserved cardiac function and reduced chronic adverse cardiac remodeling after MI. P2Y12-dependent signaling is involved in emergency hematopoiesis after MI and fuels post-ischemic inflammation, proposing a novel, non-canonical value for P2Y12 antagonists beyond inhibition of platelet-mediated atherothrombosis.
- Open Access
- 15 February 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 10, 20581-20589
Real-Time Control of Active Catheter Signals for Better Visual Profiling During Cardiovascular Interventions Under MRI Guidance
In MR-guided interventional procedures, RF coils can be attached to the instruments to provide a positive MR signal for device tracking. The signal from these coils can vary strongly over the procedure and mask the surrounding anatomy. The purpose of this study is to introduce and demonstrate a low-cost, vendor- and device-independent interface circuit that allows the interventionalist to adjust the active device signal intensity. In this work a variable attenuator circuit was constructed to control the tip signal of an active coronary artery catheter in real-time from within the MR scanner room. Performance of the attenuator circuit and the active catheter was characterized on the test bench, in a phantom model, and in vivo. The system was used in a pig model at 3T during the introduction of the catheter into the left coronary artery. The circuit could attenuate the amplitude of the tracking coil signal by up to 20 dB. Without attenuation, the tracking coil signal intensity was masking anatomical details of the coronary ostium making it impossible to reliably introduce the catheter into the artery. After interactive adjustment, which was performed in a few seconds by the interventionalist, the improved visualization of the vascular anatomy enabled a rapid insertion of the catheter into the coronary ostium. The vendor-independent variable attenuator provides real-time control of the catheter signal without interrupting the image acquisition. Even though most MRI systems can control the individual signal levels from coils by software, the attenuator hardware is advantageous as it can be integrated into any MR-system, and it provides a direct interface for the interventionalist at the magnet.
- 15 February 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 10, 20581-20589
Open AccessReal-Time Control of Active Catheter Signals for Better Visual Profiling During Cardiovascular Interventions Under MRI Guidance
In MR-guided interventional procedures, RF coils can be attached to the instruments to provide a positive MR signal for device tracking. The signal from these coils can vary strongly over the procedure and mask the surrounding anatomy. The purpose of this study is to introduce and demonstrate a low-cost, vendor- and device-independent interface circuit that allows the interventionalist to adjust the active device signal intensity. In this work a variable attenuator circuit was constructed to control the tip signal of an active coronary artery catheter in real-time from within the MR scanner room. Performance of the attenuator circuit and the active catheter was characterized on the test bench, in a phantom model, and in vivo. The system was used in a pig model at 3T during the introduction of the catheter into the left coronary artery. The circuit could attenuate the amplitude of the tracking coil signal by up to 20 dB. Without attenuation, the tracking coil signal intensity was masking anatomical details of the coronary ostium making it impossible to reliably introduce the catheter into the artery. After interactive adjustment, which was performed in a few seconds by the interventionalist, the improved visualization of the vascular anatomy enabled a rapid insertion of the catheter into the coronary ostium. The vendor-independent variable attenuator provides real-time control of the catheter signal without interrupting the image acquisition. Even though most MRI systems can control the individual signal levels from coils by software, the attenuator hardware is advantageous as it can be integrated into any MR-system, and it provides a direct interface for the interventionalist at the magnet.
- Open Access
- 27 December 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1) , 91
Use and Outcomes of Acute Treatment Strategies in Patients with Severe Aortic Valve Stenosis
This study aimed to evaluate the acute treatment of patients with severe aortic valve stenosis in Germany. Three treatment strategies in 11,027 patients acutely admitted due to aortic valve stenosis were compared from 2014 until 2018 using German nationwide records: The annual number of transcatheter aortic valve replacement (TAVR) procedures (1,294 to 1,827) and balloon valvuloplasty (BV only) procedures (170 to 233) in patients acutely admitted increased, but surgical aortic valve replacement (SAVR) procedures decreased (426 to 316). In comparison to BV only patients (mean age 81.3; EuroSCORE 23.2) SAVR patients were younger and at lower logistic EuroSCORE (mean age 66.9; EuroSCORE 9.4). Patients treated with TAVR were at comparable age and operative risk (mean age 81.3; EuroSCORE 24.4) as those patients treated with BV only. Primary outcome was in-hospital mortality. Reimbursement was considered secondary outcome. After risk adjustment using multivariable logistic and linear regression analyses, SAVR (OR 0.26 [96%CI 0.16;0.45], p < 0.001) and TAVR (OR 0.38 [0.29;0.49], p < 0.001) were associated with lower risk for mortality compared to BV only. Compared to BV only, hospitalization costs of patients undergoing SAVR were reduced by €5,578 ([95%CI €8,023; €3,133], p < 0.001). TAVR procedures were associated with higher hospitalization costs than BV only (risk-adjusted difference €4,143 [€2,330; €5,926], p < 0.001). BV only was associated with a substantially increased risk of in-hospital mortality in acute patients. We conclude that a definitive aortic valve replacement should be preferred as primary treatment in patients with severe aortic valve stenosis causing an acute admission.
- 27 December 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1) , 91
Open AccessUse and Outcomes of Acute Treatment Strategies in Patients with Severe Aortic Valve Stenosis
This study aimed to evaluate the acute treatment of patients with severe aortic valve stenosis in Germany. Three treatment strategies in 11,027 patients acutely admitted due to aortic valve stenosis were compared from 2014 until 2018 using German nationwide records: The annual number of transcatheter aortic valve replacement (TAVR) procedures (1,294 to 1,827) and balloon valvuloplasty (BV only) procedures (170 to 233) in patients acutely admitted increased, but surgical aortic valve replacement (SAVR) procedures decreased (426 to 316). In comparison to BV only patients (mean age 81.3; EuroSCORE 23.2) SAVR patients were younger and at lower logistic EuroSCORE (mean age 66.9; EuroSCORE 9.4). Patients treated with TAVR were at comparable age and operative risk (mean age 81.3; EuroSCORE 24.4) as those patients treated with BV only. Primary outcome was in-hospital mortality. Reimbursement was considered secondary outcome. After risk adjustment using multivariable logistic and linear regression analyses, SAVR (OR 0.26 [96%CI 0.16;0.45], p < 0.001) and TAVR (OR 0.38 [0.29;0.49], p < 0.001) were associated with lower risk for mortality compared to BV only. Compared to BV only, hospitalization costs of patients undergoing SAVR were reduced by €5,578 ([95%CI €8,023; €3,133], p < 0.001). TAVR procedures were associated with higher hospitalization costs than BV only (risk-adjusted difference €4,143 [€2,330; €5,926], p < 0.001). BV only was associated with a substantially increased risk of in-hospital mortality in acute patients. We conclude that a definitive aortic valve replacement should be preferred as primary treatment in patients with severe aortic valve stenosis causing an acute admission.
- Open Access
P2Y12 Inhibition in Murine Myocarditis Results in Reduced Platelet Infiltration and Preserved Ejection Fraction
Previous mouse studies have shown the increased presence of platelets in the myocardium during early stages of myocarditis and their selective detection by MRI. Here, we aimed to depict early myocarditis using molecular contrast-enhanced ultrasound of activated platelets, and to evaluate the impact of a P2Y12 receptor platelet inhibition. Experimental autoimmune myocarditis was induced in BALB/c mice by subcutaneous injection of porcine cardiac myosin and complete Freund adjuvant (CFA). Activated platelets were targeted with microbubbles (MB) coupled to a single-chain antibody that binds to the “ligand-induced binding sites” of the GPIIb/IIIa-receptor (=LIBS-MB). Alongside myocarditis induction, a group of mice received a daily dose of 100 g prasugrel for 1 month. Mice injected with myosin and CFA had a significantly deteriorated ejection fraction and histological inflammation on day 28 compared to mice only injected with myosin. Platelets infiltrated the myocardium before reduction in ejection fraction could be detected by echocardiography. No selective binding of the LIBS-MB contrast agent could be detected by either ultrasound or histology. Prasugrel therapy preserved ejection fraction and significantly reduced platelet aggregates in the myocardium compared to mice without prasugrel therapy. Therefore, P2Y12 inhibition could be a promising early therapeutic target in myocarditis, requiring further investigation.
Open AccessP2Y12 Inhibition in Murine Myocarditis Results in Reduced Platelet Infiltration and Preserved Ejection Fraction
Previous mouse studies have shown the increased presence of platelets in the myocardium during early stages of myocarditis and their selective detection by MRI. Here, we aimed to depict early myocarditis using molecular contrast-enhanced ultrasound of activated platelets, and to evaluate the impact of a P2Y12 receptor platelet inhibition. Experimental autoimmune myocarditis was induced in BALB/c mice by subcutaneous injection of porcine cardiac myosin and complete Freund adjuvant (CFA). Activated platelets were targeted with microbubbles (MB) coupled to a single-chain antibody that binds to the “ligand-induced binding sites” of the GPIIb/IIIa-receptor (=LIBS-MB). Alongside myocarditis induction, a group of mice received a daily dose of 100 g prasugrel for 1 month. Mice injected with myosin and CFA had a significantly deteriorated ejection fraction and histological inflammation on day 28 compared to mice only injected with myosin. Platelets infiltrated the myocardium before reduction in ejection fraction could be detected by echocardiography. No selective binding of the LIBS-MB contrast agent could be detected by either ultrasound or histology. Prasugrel therapy preserved ejection fraction and significantly reduced platelet aggregates in the myocardium compared to mice without prasugrel therapy. Therefore, P2Y12 inhibition could be a promising early therapeutic target in myocarditis, requiring further investigation.